IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

Triad Expands Stakes Across Allstate, MediaAlpha, Visa, Amgen — Jul 22, 2026Triad Investment Management expanded its holdings across a range of companies in the first quarter, purchasing additional shares in Allstate, MediaAlpha, Visa, and Amgen. The MediaAlpha position is particularly sizable among its new and increased stakes, underscoring a broad, diversified approach across financial services, advertising tech, payments, and biotech sectors.

0

Danica Pension Buys New AMD Stake Worth $38M — Jul 22, 2026Danica Pension Livsforsikringsaktieselskab disclosed new investments in five companies in the first quarter, taking new positions in AMD, McDonald’s, GE Vernova, Amgen, and Accenture. The moves occur amid broader institutional activity in these stocks as other investors adjust their holdings.

0

Wellington Management Expands Holdings Across Major U.S. Stocks in Q2Business — Aug 29, 2026Wellington Management Group LLP expanded or adjusted its stakes across several major U.S. companies in the latest filings, including a 97.3% increase in GE Aerospace shares and a 1,102.7% surge in Amgen holdings. It also raised its stake in Fifth Third Bancorp by 20.2% and in American International Group by 6.9%, while trimming Automatic Data Processing by 0.7%.

0

Tezspire meets Phase 3 endpoints in eosinophilic esophagitisHealth — Aug 27, 2026AstraZeneca and Amgen's Tezspire met its primary and secondary endpoints in the Phase 3 CROSSING trial for eosinophilic esophagitis, with improvements in histologic remission and reduced dysphagia sustained through week 52. The results bolster Tezspire’s potential as a multi-indication biologic across epithelial-driven inflammatory diseases, building on existing approvals for severe asthma and chronic rhinosinusitis with nasal polyps.

0

IJREXCLUSIVE: Asst. Commerce Secretary Roth Reveals The Issues Facing Classrooms That Rely Too Much On ScreensSean Moran · 6 min · 1h

Trump Arrives in Ireland Amid Tight Security — Sep 11, 2026Gardaí have imposed extensive security operations across Dublin and County Clare ahead of US President Donald Trump's visit, including temporary drone and maritime restrictions in Clare and heavy traffic controls around Doonbeg for the Amgen Irish Open. Additional measures cover rolling road closures and security checks near Dublin Airport, with protests anticipated and heightened safety at Shannon Airport while public access and parking are restricted on key routes and perimeter roads.

0

AP Top 25 College Football TeamsRankingCollege football fans argue endlessly over which programs deserve the top spots in the AP Poll based on wins, schedule strength, and legacy.

UK regulator to phase out Tavneos after finding trial data unreliable — Sep 1, 2026Britain's MHRA suspended the use and sale of Tavneos (Avacopan Vifor) for new patients after deeming the pivotal trial data unreliable, with a six-month window for continuing treatment and a planned UK market revocation by March 1, 2027. Amgen and CSL Vifor dispute the decision, arguing that the broader evidence supports the drug's benefits, while regulators in the EU and US have also flagged concerns about data reliability and potential withdrawals.

+3

Rachel Meyers If EU and US regulators are all flagging the same data problems, that's a pretty strong signal something's genuinely wrong with the trial, not just one agency being cautious.